Summary
Eli Lilly and Company (LLY) filed an 8-K on May 4, 2020, detailing the results of its annual shareholder meeting held on May 3, 2020. The report indicates strong shareholder support for the company's director nominees, executive compensation, and the ratification of Ernst & Young as its independent auditor. The overwhelming approval in these areas suggests continued confidence from the shareholder base in the company's leadership and governance. However, the filing also reveals that two significant proposals to amend the company's Articles of Incorporation did not pass. These proposals aimed to eliminate the classified board structure and remove supermajority voting provisions, both of which failed to achieve the required 80% of outstanding shares for approval. Furthermore, a substantial number of shareholder proposals, covering various aspects from lobbying activities to executive compensation and board independence, were also voted down by a significant margin, indicating a divergence in priorities between management and a portion of the shareholder base on these specific governance and operational matters.
Key Highlights
- 1All five nominated directors were overwhelmingly elected to three-year terms.
- 2Shareholders approved the executive compensation plan in an advisory vote with strong support.
- 3Ernst & Young was ratified as the principal independent auditor for fiscal year 2020 with a high majority vote.
- 4A proposal to eliminate the classified board structure did not receive the required 80% of outstanding shares for approval.
- 5A proposal to eliminate supermajority voting provisions also failed to meet the required 80% of outstanding shares for approval.
- 6Multiple shareholder proposals concerning lobbying, executive compensation, board independence, and drug pricing disclosures were not approved.
- 7As of the record date, 957,038,447 shares of common stock were issued and outstanding.